Synovial sarcoma: Immunohistochemical expression of P-glycoprotein and glutathione S transferase-pi and clinical drug resistance

• Type: Another Publication in an International Scientific Journal
• Date: 1997

Authors

Lopes, JM (Author) FMUP; Bruland, OS (Author) Other; Bjerkehagen, B (Author) Other; Silva, MC (Author) ICBAS; Holm, R (Author) Other; Pettersen, EO (Author) Other; Solheim, OP (Author) Other; SobrinhoSimoes, M (Author) FMUP; Nesland, JM (Author) Other

Journal

Title: Pathology Research and Practice

Vol. 193

Pages: 21-36

ISSN: 0344-0338

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 11 Citations

Scopus - 9 Citations

Scientific classification

FOS: Medical and Health sciences > Basic medicine

Other information

Authenticus ID: P-001-CT7

DOI: 10.1016/s0344-0338(97)80090-8

Abstract (EN): Our purpose was to study the role of the expression of P-glycoprotein (Pgp) and glutatione S transferase-pi (GST-pi) in predicting the response to chemotherapy, relapse-free interval, and survival of patients with synovial sarcoma (SS). Thirty-seven cases of primary SS, without regional lymph node or distant metastases, were studied. There were 17 females and 20 males, ranging in age from 7 to 81 years (median, 31 years) with tumors located in the lower extremity (n = 24) upper extremity (n = 5) and trunchus (n = 8). The cases were retrospectively studied without knowledge of clinical course to compare the immunohistochemical expression of Pgp and GST-pi, flow cytometry parameters (ploidy and % of cells in S+G2 phases), and PCNA and Ki-67 labeling of primary tumors before any therapy, with that observed in local recurrences and metastases after chemotherapy. The relationship of the aforementioned parameters with clinicopathological features (gender, age, and histoblood group of the patients, size, location, histological subtype, TNM stage, and clinical response to chemotherapy of the tumors) was also evaluated. Results revealed that Pgp and GST-pi were expressed in 29.7% and 40.5% of the cases, respectively. In 48.6% of the tumors there was expression of at least one of the drug resistance markers. The markers were coexpressed in 25.0% Of the tumors. The prevalence of Pgp expression was lower, but not significantly, in stage I-II (17.6%) than in stage III (40.0%) tumors, and also in cases without clinical progression (16.7%), than in cases with (36.0%). No such differences were observed for GST-pi expression. Pgp and GST-pi expressions were significantly associated with biphasic SS and were particularly noticeable in solid/glandular areas of biphasic SS. The expression of the drug resistance markers was not significantly associated with gender, age, and histo-blood group of the patients, dimension, location, and proliferative activity of the tumors; it was also not significantly related to relapse-free interval and survival of the patients. The expression of Pgp and GST-pi was not significantly associated either to response to chemotherapy or influenced by chemotherapy. We conclude that Pgp and GST-pi expressions are not good predictors response to of the chemotherapy in patients with localized SS. Other drug resistance mechanisms may be active in SS.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 16